[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"synovitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:synovitis":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,84,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100493094","perfusion-mri-targeted-joint-embolization-for-chronic-musculoskeletal-pain-of-the-shoulder-hip-and-knee-100493094",false,"NCT05700682","Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee","Perfusion MRI-targeted Joint Embolization to Diagnose and Treat Neovascularity Associated With Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee: A Prospective Cohort Study","MRI","Inclusion Criteria (Both Arms):\n\n1. Participants must be Veterans who receive care in the VA system.\n2. Participants must have a history of chronic pain of the shoulder, hip or knee for at least 1 year.\n3. Participants must have mild to moderate degenerative changes of the painful joint as depicted on prior imaging (X-ray, CT or MRI).\n4. Participants must have undergone at least one failed primary treatment for their chronic pain (e.g. physical therapy, NSAIDs, steroid injection).\n5. Participants must have an MRI of their painful joint (shoulder, hip or knee) ordered by a clinical provider.\n\nInclusion Criteria (Therapeutic Arm):\n\n1. Participants must have enrolled in the Diagnostic Arm of the study and must have undergone perfusion MR imaging of their painful joint.\n2. Participants must have evidence of peri-articular hypervascularity on their perfusion MR exams. This will be determined by the study PIs.\n\nExclusion Criteria (Diagnostic Arm):\n\n1. Acute injury in the last 12 weeks.\n2. Age under 25.\n3. Severe degenerative changes of painful joint (shoulder, hip or knee).\n4. History of arthroplasty or metallic implant within the painful joint.\n5. Severe gadolinium contrast allergy.\n6. Severe renal disease or ongoing dialysis.\n7. History of malignancy with life expectancy of less than one year, or malignancy with known bone metastasis.\n8. Current pregnancy.\n9. Formal diagnosis of cognitive impairment.\n\nExclusion Criteria (Therapeutic Arm):\n\n1. Severe iodinated contrast allergy.\n2. Severe coronary or peripheral arterial disease.\n3. Coagulopathy.\n4. Uncontrolled type 2 diabetes or diabetic neuropathy.\n5. History of seizures or other severe complication from conscious sedation.\n6. Prior upper or lower extremity arterial bypass.\n7. Ongoing participation in another interventional (therapeutic) trial for chronic joint pain.\n8. Lack of peri-articular hypervascularity on initial perfusion MRI.\n9. All exclusion criteria for the Diagnostic Arm.","ALL","25 Years","80 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","In this work the investigators will study the relationship between chronic musculoskeletal pain and abnormal blood flow (neovascularity) around the shoulder, hip and knee. Veterans with as history of chronic shoulder, hip or knee pain and mild\u002Fmoderate joint degenerative changes will be potential study subjects. Blood flow around joints will be evaluated using perfusion magnetic resonance imaging (MRI). Participants with demonstrably abnormal blood flow around their painful joint will be eligible for enrollment in a pilot study of joint embolization to treat their pain. Participants who choose to not undergo treatment will be re-assessed with MRI after one year to characterize the natural history of joint neovascularity and its relationship to pain.",[26,27,28,29,30,31,32],"Osteoarthritis, Knee","Osteoarthritis, Hip","Osteo Arthritis Shoulders","Synovitis of Knee","Synovitis\u002FTenosynovitis - Hip","Synovitis","Pain, Chronic",[34,35,36,37,38,39,40],"joint","embolization","neovascularity","pain","knee","hip","shoulder","RECRUITING","2025-08-04",{"date":44,"type":45},"2025-08-07","ACTUAL",{"date":47,"type":45},"2023-07-15",{"date":49,"type":22},"2026-08-01",{"name":51,"class":52},"Palo Alto Veterans Institute for Research","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":63,"studyType":23,"phases":4,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100572798","cellular-and-molecular-analysis-of-synovial-tissue-of-patients-with-arthritis-100572798","NCT06737952","Cellular and Molecular Analysis of Synovial Tissue of Patients With Arthritis","Inclusion Criteria:\n\n* Age \\>18 years\n* Clinically relevant arthritis in one or more joints as assessed by the treating rheumatologist, including RA, SpA, connective tissue disease and OA.\n\nExclusion Criteria:\n\n* Known allergies to local anesthetics\n* Family history of bleeding, history of increased bleeding tendency or prolonged bleeding, current treatment with oral anticoagulants or platelet aggregation inhibitors; Quick \\\u003C 65%, international normalised ratio (INR) ≥ 1.3, thrombocyte count \\\u003C 100'000\u002Fμl, activated partial thromboplastin time (aPTT) \\> 37 sec\n* Inability or insufficient knowledge of project language to understand the information given in the informed consent form","18 Years",{"count":62,"type":22},90,"5 Days","This study aims to study the inflammatory response in various forms of arthritis.",[66,67,68,69,31],"Arthritis","Arthritis, Rheumatoid","Osteoarthritis","Spondyloarthritis",[71,72,73],"ultrasound-guided synovial biopsies (UGSB)","inflammatory response","synovial biopsy","NOT_YET_RECRUITING","2025-04-08",{"date":77,"type":45},"2025-04-11",{"date":79,"type":22},"2025-05",{"date":81,"type":22},"2029-12",{"name":83,"class":52},"University Hospital, Basel, Switzerland",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":92,"minAge":60,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":53},"100543157","prevalence-of-synovitis-in-patients-with-haemophilia-a-100543157","NCT06352216","Prevalence of Synovitis in Patients With Haemophilia A","Prevalence of Synovitis in Adult Patients With Haemophilia A in Germany and Austria","SynoPrev","Inclusion Criteria:\n\n* Participants (≥ 18 years old) suffering from moderate or severe haemophilia A, also with inhibitor or joint replacement\n* Complete documentation of hemophilia severity, treatment history (past 12 months), and bleeding events (past 12 months), inhibitor status (at time of enrollment and in past medical history)\n* Submitted written consent to participate in the study\n\nExclusion Criteria:\n\n* Patients suffering from other bleeding disorders conflicting with the research question\n* Patients in clinical studies with investigational drugs","MALE",{"count":94,"type":22},300,"The aim of this study is to evaluate the prevalence of synovitis in adult patients with haemophilia A.",[97,31,98,99],"Haemophilia A","Hemophilia Arthropathy","Sonography",[31,97,101],"Prevalence","2024-04-15",{"date":104,"type":45},"2024-04-16",{"date":102,"type":45},{"date":107,"type":22},"2027-03",{"name":109,"class":52},"University Hospital, Bonn",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":53},"100487595","embolization-in-hereditary-coagulopathies-100487595","NCT05629130","Embolization in Hereditary Coagulopathies","EHCO","Inclusion Criteria:\n\n* Patients with hereditary coagulopathies with arthropathy (i.e., chronic synovitis due to hemarthrosis), with X-ray and MRI (documenting synovitis) followed up at the Hemophilia Center HC-FMUSP.\n\nExclusion Criteria:\n\n* Patients who do not complete the planned assessments\n* Patients who do not accept to continue with the study.",{"count":118,"type":22},30,"INTERVENTIONAL",[121],"NA","This is a longitudinal, prospective study, which will include 30 subjects with hereditary coagulopathies, with arthropathy, chronic synovitis resulting from hemarthrosis of the elbows, knees and\u002For ankles followed up at the Centro de Hemofilia HCFMUSP, after approval by the ethics and research committee.\n\nThey will undergo imaging tests (X-rays and Magnetic Resonance of knee, elbow, or ankle), physical, pain, quality of life and functional assessments (Hemophilia Joint Health Score, Functional Independence Score in Hemophilia, Perimeter, Test Timed up and Go, 30 second sit and stand test, Haemophilia - Adult - Quality of Life questionnaire (HAEM-A-QoL), Knee Injury and Osteoarthritis Outcome Score, EQ-5D, numerical rating scale for pain and embolization procedure (superselective embolization of target arteries with spherical microparticles Embosphere 100-300 micrometers (Biosphere Medical, Roissy, France), until partial vascular stasis and decharacterization of pathological synovial enhancement.\n\nThese evaluations will be performed at baseline, 1, 3, 6, 12, 24, 36, 48 and 60 months after the procedure.",[124,125,126,127,31,128],"Hemophilia","Embolization","Hemarthrosis","Clotting Factor Deficiency","Arthropathy","2022-11-16",{"date":131,"type":45},"2022-11-29",{"date":133,"type":22},"2023-01-16",{"date":135,"type":22},"2029-12-31",{"name":137,"class":52},"University of Sao Paulo General Hospital"]